Literature DB >> 20484568

Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever.

Ana Saksida1, Darja Duh, Branka Wraber, Isuf Dedushaj, Salih Ahmeti, Tatjana Avsic-Zupanc.   

Abstract

Until now, the pathogenesis of Crimean-Congo hemorrhagic fever (CCHF) has not been well described. However, it has been hypothesized that it could be a result of the direct injury of virus-infected tissues in combination with the indirect effects of host immune responses, including cytokines. To shed more light on the role of viral load and cytokines, differential influences of CCHF virus (CCHFV) RNA load, antibody response, and cytokine production on severity and outcome of the disease were studied in sera of 46 patients with confirmed acute CCHF from Kosovo. In this study, viral load proved to be strongly related to the severity and outcome of the disease, with higher viral loads detected in patients with fatal outcomes than in surviving patients. Also, patients with fatal outcome had on average a weaker antibody response, if one was present at all. High levels of interleukin-10 (IL-10), gamma interferon (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha) were associated with poor outcome, since detected concentrations were highest in patients with fatal outcome and lowest in patients with moderate disease course. Additionally, a positive linear dependence between viral load and these cytokines was observed. Interestingly, reduced levels of IL-12 were detected in all CCHF patients. Our study favors the hypothesis that CCHF could be a result of a delayed and downregulated immune response caused by IL-10, which leads to an increased replication and spread of CCHFV throughout the body. This consequently triggers increased production of IFN-gamma and TNF-alpha, cytokines mediating vascular dysfunction, disseminated intravascular coagulation, organ failure, and shock.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484568      PMCID: PMC2897258          DOI: 10.1128/CVI.00530-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.

Authors:  Daniel H Libraty; Timothy P Endy; Huo-Shu H Houng; Sharone Green; Siripen Kalayanarooj; Saroj Suntayakorn; Wanya Chansiriwongs; David W Vaughn; Ananda Nisalak; Francis A Ennis; Alan L Rothman
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

Review 2.  Viral hemorrhagic fever--a vascular disease?

Authors:  Hans-J Schnittler; Heinz Feldmann
Journal:  Thromb Haemost       Date:  2003-06       Impact factor: 5.249

3.  High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis.

Authors:  Wei-Kung Wang; Day-Yu Chao; Chuan-Liang Kao; Han-Chung Wu; Yung-Ching Liu; Chien-Ming Li; Shih-Chung Lin; Shih-Ting Ho; Jyh-Hsiung Huang; Chwan-Chuen King
Journal:  Virology       Date:  2003-01-20       Impact factor: 3.616

4.  Monitoring of clinical and laboratory data in two cases of imported Lassa fever.

Authors:  Herbert Schmitz; Bernhard Köhler; Thomas Laue; Christian Drosten; Peter J Veldkamp; Stephan Günther; Petra Emmerich; Hans P Geisen; Klaus Fleischer; Matthias F C Beersma; Achim Hoerauf
Journal:  Microbes Infect       Date:  2002-01       Impact factor: 2.700

5.  Inflammatory responses in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; A J Georges; M-C Georges-Courbot; M Capron; I Bedjabaga; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

6.  Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections.

Authors:  Susan J Gagnon; Masuko Mori; Ichiro Kurane; Sharone Green; David W Vaughn; Siripen Kalayanarooj; Saroj Suntayakorn; Francis A Ennis; Alan L Rothman
Journal:  J Med Virol       Date:  2002-05       Impact factor: 2.327

7.  Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles.

Authors:  Thanh Hung Nguyen; Huan-Yao Lei; Trong Lan Nguyen; Yee-Shin Lin; Kao-Jean Huang; Bich Lien Le; Chiou-Feng Lin; Trai-Ming Yeh; Quang Ha Do; Thi Que Huong Vu; Lien-Cheng Chen; Jyh-Hsiung Huang; Thi My Lam; Ching-Chuan Liu; Scott B Halstead
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

8.  Crimean Congo hemorrhagic fever virus infects human monocyte-derived dendritic cells.

Authors:  Anne-Marie Connolly-Andersen; Iyadh Douagi; Annette A Kraus; Ali Mirazimi
Journal:  Virology       Date:  2009-06-30       Impact factor: 3.616

9.  Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome.

Authors:  Jonathan S Towner; Pierre E Rollin; Daniel G Bausch; Anthony Sanchez; Sharon M Crary; Martin Vincent; William F Lee; Christina F Spiropoulou; Thomas G Ksiazek; Mathew Lukwiya; Felix Kaducu; Robert Downing; Stuart T Nichol
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran.

Authors:  M Mardani; M Keshtkar Jahromi; K Holakouie Naieni; M Zeinali
Journal:  Clin Infect Dis       Date:  2003-06-04       Impact factor: 9.079

View more
  39 in total

1.  Crimean-Congo hemorrhagic fever virus activates endothelial cells.

Authors:  Anne-Marie Connolly-Andersen; Guido Moll; Cecilia Andersson; Sara Akerström; Helen Karlberg; Iyadh Douagi; Ali Mirazimi
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Interleukin-12 (IL-12)/IL-10 ratio as a marker of disease severity in Crimean-Congo hemorrhagic fever.

Authors:  Dionysios C Watson; Maria Sargianou; George Panos
Journal:  Clin Vaccine Immunol       Date:  2012-05

3.  Evaluation of cytokines as Th1/Th2 markers in pathogenesis of children with Crimean-Congo hemorrhagic fever.

Authors:  Enver Sancakdar; Ahmet Sami Güven; Elif Bilge Uysal; Ali Kaya; Köksal Deveci; Hekim Karapınar; Ismail Akkar
Journal:  Int J Clin Exp Med       Date:  2014-03-15

4.  Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Authors:  Michael E Lindquist; Xiankun Zeng; Louis A Altamura; Sharon P Daye; Korey L Delp; Candace Blancett; Kayla M Coffin; Jeffrey W Koehler; Susan Coyne; Charles J Shoemaker; Aura R Garrison; Joseph W Golden
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

5.  Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Authors:  David W Hawman; Kimberly Meade-White; Elaine Haddock; Rumi Habib; Dana Scott; Tina Thomas; Rebecca Rosenke; Heinz Feldmann
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

6.  Therapeutic intervention in Crimean-Congo hemorrhagic fever: where are we now?

Authors:  Jessica R Spengler; Dennis A Bente
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

7.  Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy.

Authors:  Marko Zivcec; David Safronetz; Dana Scott; Shelly Robertson; Hideki Ebihara; Heinz Feldmann
Journal:  J Infect Dis       Date:  2013-02-15       Impact factor: 5.226

8.  Serum resistin levels may be new prognostic factor of crimean-congo hemorrhagic fever.

Authors:  Ayse Erturk; Erkan Cure; Emine Parlak; Medine Cumhur Cure; Suleyman Yuce; Bayram Kizilkaya
Journal:  Int J Clin Exp Med       Date:  2014-10-15

9.  Severe Crimean-Congo haemorrhagic fever presented with massive retroperitoneal haemorrhage that recovered without antiviral treatment.

Authors:  Mehrnaz Asadi Gharabaghi; Sadegh Chinikar; Seyyed Mojtaba Ghiasi; Maryam Morady; Taha Ahmadinejhad; Koosha Paydary
Journal:  BMJ Case Rep       Date:  2011-08-19

10.  Second International Conference on Crimean-Congo Hemorrhagic Fever.

Authors:  Jessica R Spengler; Dennis A Bente; Mike Bray; Felicity Burt; Roger Hewson; Gülay Korukluoglu; Ali Mirazimi; Friedemann Weber; Anna Papa
Journal:  Antiviral Res       Date:  2017-12-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.